Drugs / Lisuride
Lisuride
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00000338 | Mar 1996 → ? | cocaine dependence | National Institute on Drug Abuse (NIDA) | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00089622 | Aug 2004 → Mar 2007 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00408915 | Jul 2006 → ? | Parkinson disease | Axxonis Pharma AG | Completed | No outcome recorded |
| Phase 3 | NCT00367822 | — | restless legs syndrome | Axxonis Pharma AG | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lisuride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00367822 ↗ |
| Known as | Lisurida | ChEMBL registry synonym — accepted as the source's own label CHEMBL157138 ↗ |
| Known as | Lisuride maleate | ChEMBL registry synonym — accepted as the source's own label CHEMBL157138 ↗ |
| Known as | Lysuride maleate | ChEMBL registry synonym — accepted as the source's own label CHEMBL157138 ↗ |
| Known as | Revanil 200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL157138 ↗ |
| Modality | Small molecule | — CHEMBL157138 ↗ |
| Route | Other | “A novel transcutaneous formulation of the dopamine agonist lisuride will be used” NCT00089622 ↗ |